Navigation Links
Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability

MOUNTAIN VIEW, Calif. and STANFORD, Calif., April 21, 2011 /PRNewswire/ -- The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries. For details regarding this clinical trial, please refer to the website

SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of stroke disability.   "SB623 represents a significant step forward in the development of regenerative therapies for the treatment of brain injury," said Keita Mori, SanBio CEO.   "We are pleased to initiate a first-in-man study of SB623."

SB623 will be administered by intracranial injection into the damaged region of the brains of patients who have suffered an ischemic stroke.  Product safety is the primary focus of the study but various measurements of efficacy will also be tested.

"This is a completely new approach to therapy for stroke victims," said Dr. Gary Steinberg, the Lacroute-Hearst Professor, Chairman of the Department of Neurosurgery, and Director of the Stanford Institute for Neuro-Innovation and Translational Neurosciences at the Stanford University School of Medicine, and Principal Investigator of the study.  Sub-Investigator Dr. Neil Schwartz, Clinical Assistant Professor of Neurology, Stanford Stroke Center, said, "If successful, this cell therapy offers hope to otherwise permanently disabled patients."

About SB623: SB623 is a proprietary regenerative cell therapy consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors.  SB623 is implanted directly adjacent to the area damaged by stroke and functions by producing proteins that aid the healing process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

About Stanford: Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics, and Lucile Packard Children's Hospital.  For more information, please visit the Office of Communication & Public Affairs site at

For more information:

SOURCE SanBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Stanford: Quantum computing spins closer
3. Cell Biosciences Delivers Next Generation System to Stanford University
4. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
5. Stanford writes in worlds smallest letters
6. Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center
7. Stanford researchers find a quicker, cheaper way to sort isotopes
8. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
9. LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory
10. New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher
11. Stanford scientists develop new way to grow adult stem cells in culture
Post Your Comments:
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... are paramount. Insertion points for in-line sensors can represent a weak spot where ... InTrac 781/784 series of retractable sensor housings , which are designed to tolerate ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
Breaking Biology News(10 mins):